EMILIA supports Roche's T-DM1 filing but MARIANNE will be key to market performance
This article was originally published in Scrip
Executive Summary
Roche is planning to file this year for US and EU approval of T-DM1, the antibody drug conjugate version of its breast cancer drug Herceptin, following positive top-line results from a Phase III trial. While the news is welcome, a key uncertainty remains regarding the drug's commercial potential: how it will stack up against Herceptin (trastuzumab) itself. Overall survival data are also yet to be reported.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.